Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Pharmaceuticals (Basel, Switzerland)
|
September 23, 2015
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
Natalie S Grover, Steven I Park
Current Opinion in Hematology
|
September 28, 2007
Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
Steven I Park, Oliver W Press
Science Advances
|
April 10, 2020
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma
Kin Man Au, Andrew Z Wang, Steven I Park
Science Advances
|
September 14, 2020
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Kin Man Au, Steven I Park, Andrew Z Wang
Leukemia & Lymphoma
|
January 6, 2018
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis
Christopher Dittus, Natalie Grover, Steven Ellsworth, et al.
Molecular Biosystems
|
November 26, 2010
A pretargeted nanoparticle system for tumor cell labeling
Jonathan Gunn, Steven I Park, Omid Veiseh, et al.
ACS Central Science
|
May 27, 2024
Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
ACS Central Science
|
January 30, 2019
High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
The Annals of Pharmacotherapy
|
October 26, 2019
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas
Donald C Moore, Joseph B Elmes, Priscila A Shibu, et al.
ACS Central Science
|
March 30, 2026
Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Pharmaceuticals (Basel, Switzerland)
|
September 23, 2015
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
Natalie S Grover, Steven I Park
Current Opinion in Hematology
|
September 28, 2007
Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
Steven I Park, Oliver W Press
Science Advances
|
April 10, 2020
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma
Kin Man Au, Andrew Z Wang, Steven I Park
Science Advances
|
September 14, 2020
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Kin Man Au, Steven I Park, Andrew Z Wang
Leukemia & Lymphoma
|
January 6, 2018
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis
Christopher Dittus, Natalie Grover, Steven Ellsworth, et al.
Molecular Biosystems
|
November 26, 2010
A pretargeted nanoparticle system for tumor cell labeling
Jonathan Gunn, Steven I Park, Omid Veiseh, et al.
ACS Central Science
|
May 27, 2024
Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
ACS Central Science
|
January 30, 2019
High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
The Annals of Pharmacotherapy
|
October 26, 2019
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas
Donald C Moore, Joseph B Elmes, Priscila A Shibu, et al.
ACS Central Science
|
March 30, 2026
Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"
Kin Man Au, Rod Balhorn, Monique C Balhorn, et al.
Page
of 5